AIM ImmunoTech (STU:HXB) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


STU:HXB AIM ImmunoTech Inc STU:HXB
33 GF Score
Price €5.76
GF Value €49.66
! 6 Warning Signs
View Full Analysis

What is AIM ImmunoTech Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

AIM ImmunoTech's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

STU:HXB vs BGMS, FBLG, CLGN: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, AIM ImmunoTech's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AIM ImmunoTech Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's Margin of Safety % (DCF Earnings Based) falls into.


STU:HXB
33GF Score
AIM ImmunoTech Inc STU:HXB
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AIM ImmunoTech (STU:HXB) Overvalued in 2026?

Based on GuruFocus' analysis, AIM ImmunoTech stock appears to be undervalued. The current stock price of €5.76 is trading 88.4% below its estimated GF Value™ of €49.66.

Key valuation signals for STU:HXB:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €49.66 vs. price of €5.76 (88.4% below fair value)
  • GF Score™: 33/100 with 6 warning signs

No single metric tells the full story. See the STU:HXB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AIM ImmunoTech Business Description

Other Exchanges AIM:USA0A4Y:UK
Address 2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
33GF Score

Get the complete analysis for STU:HXB

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.76
Price
€49.66
GF Value